- Home
- NHC vs DNTH Comparison
NHC vs DNTH Comparison
Compare NHC & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NHC | DNTH |
|---|---|---|
| Founded | 1971 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hospital/Nursing Management | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.9B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | NHC | DNTH |
|---|---|---|
| Price | $139.75 | $54.24 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $68.88 |
| AVG Volume (30 Days) | 68.8K | ★ 819.1K |
| Earning Date | 02-26-2026 | 03-10-2026 |
| Dividend Yield | ★ 1.83% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 6.48 | N/A |
| Revenue | ★ $1,500,618,000.00 | $3,078,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $21.62 | ★ N/A |
| Revenue Growth | ★ 22.67 | N/A |
| 52 Week Low | $89.14 | $13.37 |
| 52 Week High | $146.74 | $54.59 |
Technical Indicators
Market Signals| Indicator | NHC | DNTH |
|---|---|---|
| Relative Strength Index (RSI) | 52.96 | 71.83 |
| Support Level | $141.37 | $48.86 |
| Resistance Level | $146.74 | $52.02 |
| Average True Range (ATR) | 4.02 | 3.21 |
| MACD | 0.23 | 0.96 |
| Stochastic Oscillator | 61.24 | 97.37 |
Price Performance
Historical ComparisonAbout NHC National HealthCare Corporation
National Healthcare Corp Provides long-term care facilities. Its principal business includes the operation of skilled nursing facilities, assisted living facilities, independent living facilities, and home care programs. The company's activities include providing sub-acute and post-acute skilled nursing care, intermediate nursing care, rehabilitative care, memory and Alzheimer's care, senior living services, and home health care services. In addition, the company also provides management services, accounting, and financial services, as well as insurance services to third-party operators of healthcare facilities. Its reportable segments include Inpatient services, and Home care hospice services. Generating, a majority of its revenue from Inpatient services.
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.